<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="78853">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01811446</url>
  </required_header>
  <id_info>
    <org_study_id>CLP-2.00</org_study_id>
    <nct_id>NCT01811446</nct_id>
  </id_info>
  <brief_title>Evaluation of Muscle Activation Efficiency in Challenging Subjects</brief_title>
  <official_title>Evaluation of Muscle Stimulation Efficiency in Challenging Subjects: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Niveus Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Niveus Medical, Inc.</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether muscle activation can be accomplished more
      effectively and comfortably in challenging subjects using novel configurations of an
      activation device. A novel device will be compared side by side with a market leading
      device.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Intensity Required</measure>
    <time_frame>During treatment</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Intensity required to achieve target levels of muscle contraction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comfort</measure>
    <time_frame>During treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Comfort of stimulation will be assessed at various intensity levels using a widely-used discomfort scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Obesity</condition>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>Obese</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with BMI &gt; 30</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COPD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-hospitalized COPD patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Muscle Activation with Niveus and Intelect Devices</intervention_name>
    <description>Subjects will receive muscle activation technology from the Niveus device on one leg and from the Intelect (commercially-available third-party) device on the other. The order of use and the leg applied to will be randomized.</description>
    <arm_group_label>Obese</arm_group_label>
    <arm_group_label>COPD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI &gt; 30 (Wing 1 of study)

          -  Non-hospitalized with confirmed diagnosis of COPD (Wing 2 of study)

        Exclusion Criteria:

          -  Age &lt; 18 years

          -  Subject has an implanted pacemaker/defibrillator

          -  Subject diagnosed with epilepsy

          -  Subject has implanted metallic femoral rods

          -  Subject is chair- or bed-bound

          -  Subject has neuromuscular disease or abnormalities

          -  Subject BMI &gt; 45

          -  Evidence of disease or condition that, in the opinion of the investigator, may
             compromise the conduct of or results of the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bahman Nouri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>El Camino Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fogarty Clinical Research</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 29, 2014</lastchanged_date>
  <firstreceived_date>March 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
